Sarcoma  >>  semaxanib (SU5416)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
semaxanib (SU5416) / Pfizer
NCT00005042: SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed
2
US
semaxanib
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Sarcoma
11/00
11/00
NCT00005862: SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Completed
2
60
US
semaxanib
National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Sarcoma
07/04
 
NCT00005931: SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment

Completed
2
30
US
SU5416
SUGEN
Sarcoma, Kaposi, HIV Infections
 
 
NCT00023725: Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma

Completed
1/2
US, Canada
semaxanib, conventional surgery, radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI)
Sarcoma
 
10/03
NCT00023738: Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

Completed
1/2
US, Canada
filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, semaxanib, conventional surgery, radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI)
Sarcoma
 
10/03

Download Options